Дункан Кармайкл - Молодость навсегда. Как замедлить процессы старения и сохранить здоровье

Schumacher, M. ‘Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelin.’ Growth Horm IGF Res (2004): 14 Suppl a: S 18–33.

Stein, D. G. ‘Progesterone exerts neuroprotective effects after brain injury.’ Brain Res Rev (2008): 57 (2): 386–397.

Arbo, B. D. et al. ‘Asymmetric effects of low doses of progesterone on GABA(A) receptor α4 subunit protein expression in the olfactory bulb of female rats.’ Can J Physiol Pharmacol (2014): 92: 1–5.

Von Broekhoven, F. et al. ‘Neurosteroids in depression: a review.’ Psychopharmacology (2003): 165: 97–110.

Sitruk-Ware, R. et al. ‘Progesterone and related progestins: potential new health benefits.’ Climacteric (2013): 16 Suppl 1: 69–78.

Nilsen, J. et al. ‘Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate.’ Endocrinology (2002): 143: 205–212. Boomsma, D. and Paoletti, J. ‘A review on the current research on the effects of progesterone.’ Int J Pharm Compd (July/August 2002): (6) 4.

Stein, D. G. ‘The case for progesterone.’ Ann NY Acad Sci (2005): 1052: 152–69.

Mauvais-Jarvis, M. et al. ‘Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone.’ J Clin Endocrinol Metabolism (1974): 38 (1): 142–147.

Oettel, M. et al. ‘Progesterone: the forgotten hormone in men?’ The Aging Male (2004): 7: 236–257.

Cassidenti, G. L. et al. ‘Effects of sex steroids on skin 5 alpha-reductase activity in vitro.’ Obstet Gynecol (1991): 78: 103–107.

Singh, M. K. et al. ‘Persistent Sexual Dysfunction and Depression in Finasteride Users for Male Pattern Hair Loss. A Serious Concern or Red Herring?’ J Clin Aesthet Derm (2014): 7: 51–55.

Bhasin, S. et al. ‘Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline.’ J Clin Endocrinol Metab (1997): 82: 407–413.

‘FDA In Brief: FDA warns against using SARMs in body-building products.’ Press Release FDA (31 October 2017).

Mof at, S. D. et al. ‘Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men.’ J Clin Endocrinol Metab (2002): 87: 5001–5007.

Mof at, S. D. et al. ‘Free testosterone and risk for Alzheimer’s disease in older men.’ Neurology (2004): 62: 188–193.

Beer, T. M. et al. ‘Testosterone loss and Estradiol administration modify memory in men.’ J Urol (2006): 175: 130–135.

Haider, K. S. et al. ‘Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.’ J Urol (2018): 199: 257–265.

‘Divorce after 50 grows more common.’ The New York Times (22 September 2013).

Gold, E. B. ‘The timing of the age at which natural menopause occurs.’ Obstet Gynecol Clin North Am (2011): 38: 425–440.

Hersh, A. L. et al. ‘National use of postmenopausal hormone therapy: annual trends and response to recent evidence.’ JAMA (2004): 291 (1): 47–53.

Pal, L. et al. ‘The Women’s Health Initiative: an unforgettable decade.’ Menopause (2012): 19: 597–599.

Hersh, A. L. et al. ‘National use of postmenopausal hormone therapy: annual trends and response to recent evidence.’ JAMA (2004): 291 (1): 47–53d.

Sarrel, P. M. et al. ‘The mortality toll of oestrogen avoidance: an analysis of excessive deaths among hysterectomized women aged 50 to 59 years.’ Am J Public Health (2013): 103: 1583–1588.

Barrett-Connor, E. ‘Sex dif erences in coronary heart disease. Why are women so superior?’ The 1995 Ancel Keys Lecture. Circulation (1997): 95: 252–264.

Wellons, M. ‘Early menopause associated with increased risk of heart disease, stroke.’ John Hopkins Medicine (2012).

Campos, H. et al. ‘Effect of oestrogen on very low-dose density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women.’ J Clin Endocrinol Metab (1997): 82 (12): 3955–3963.

Mendelsohn, M. E. and Karas, R. H. ‘The protective effects of oestrogen on the cardiovascular system.’ N Engl J Med (1990): 340: 1111–1801.

Barrett-Connor, E. ‘Sex dif erences in coronary heart disease. Why are women so superior? The 1995 Ancel keys lecture.’ Circulation (1997): 95: 252–264.

Grodstein, F. et al. ‘Postmenopausal estrogen and progestin use and the risk of cardiovascular disease.’ N Engl J Med (1996): 335 (7): 453–461.

Blakely, J. A. ‘The Heart and Estrogen/Progestin Replacement Study Revisited. Hormone Replacement Therapy Produced Net Harm, Consistent With the Observational Data.’ JAMA (2000): 160: 2897–2900.

‘Hormone Replacement Study A Shock to the Medical System’, The New York Times (10 July 2002). URL: http://www.nytimes.com/2002/07/10/us/hormone-replacement-study-a-shock-to-the-medical-system.html?pagewanted=all.

Grodstein, F. et al. ‘Postmenopausal hormone therapy and mortality.’ N Engl J Med (1997): 336: 1769–1776.

Rossouw, E. et al. ‘Lessons learned from the Women’s Health Initiative trials of meno-pausal hormone therapy.’ Obstet Gynecol (2003): 121: 172–176. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 3547645/.

Anderson, G. L. et al. ‘Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.’ JAMA (2004): 291: 1701–1712.

Rossouw, J. et al. ‘Writing group for the Women’s Health Initiative randomized controlled trial.’ JAMA (2002): 288: 321–333.

http://www.icis.com/resources/news/2002/07/17/177264/wyeth-shares-fall-11-to-new-low-on-hormone-drug-fears/.

Sarrel, P. M. et al. ‘The mortality toll of oestrogen avoidance: an analysis of excessive deaths among hysterectomized women aged 50 to 59 years.’ Am J Public Health(2013): 103: 1583–1588.

Schierbeck, L. L. et al. ‘Effect of hormone replacement therapy on cardiovascular events in recently post-menopausal women: randomised trial’. BMJ (2012): 345: e6409.

Sarrel, P. M. et al. ‘The mortality toll of oestrogen avoidance: an analysis of excessive deaths among hysterectomized women aged 50 to 59 years.’ Am J Public Health (2013): 103: 1583–1588.

Renoux, C. et al. ‘Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.’ BMJ (2010): 340: c2519.